Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 3Neoplasms 2Agnosia 2Thyroid Neoplasms 1Postoperative Analgesia 1Pain, Intractable 1Neoplasm Metastasis 1Inflammation 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × Dexmedetomidine × Clear all
NCT03936205 2019-05-14

Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

Hotel Dieu de France Hospital

Phase 2/3 Completed
18 enrolled

Neoplasm Metastasis, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡